tirzepatide vision loss risks in patients using popular GLP-1 medications raise concerns Zepbound and Vision Loss: An

As of August 2024, three doses of Wegovy remain in limited availability: 0.25 mg/0.5 mL 0.5 mg/0.5 mL 1 mg/0.5 mL The FDA database lists the estimated shortage duration for these doses as "TBD" (To Be Determined)

ENTER: GLP-1 agonists

Coming Soon

In clinical trials, GI side effects occur in roughly 4050% of patients on either medication, though they are typically mild to moderate and tend to improve over the first 812 weeks

Most other medications for helping in the management of blood sugar levels are not recommended for those under 18 years of age, but Mounjaro (tirzepatide), though has so far proven to be slightly less effective in young people, is still undergoing clinical trials to fully explore its efficacy with helping young people manage their type 2 diabetes with more ease